ALSO READSanofi India Q4 net jumps 44% to Rs 76 cr Brazil's EMS and India's Torrent Pharma vying for Sanofi's generic drugs: sources Sanofi pins hopes on 2018 for growth after recent takeover deals Drugmaker Sanofi sees return to profit growth this year Sanofi's return to profit growth this year slower than hoped
PARIS (Reuters) - French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday.
Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.
Earlier this week, it sold some brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros.
"Following a comprehensive review of strategic options for our generics unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success," Sanofi Chief Executive Olivier Brandicourt said in a statement.
The planned sale of Zentiva began in October after Sanofi spent more than a year carving out the division to create a stand-alone company that could be sold to one of its competitors or to an investment fund.
In February, sources told Reuters that private equity firms Carlyle, BC Partners and a consortium of Blackstone and Nordic Capital, had been shortlisted to buy Zentiva along with two industry players, Brazilian drugs firm EMS and India's Torrent Pharma.
Zentiva operates in 50 markets and has a strong presence in Eastern Europe, particularly in the Czech Republic, Slovakia and Romania. Its generic drugs portfolio includes cardiovascular and gastrointestinal drugs as well as painkillers and anti-inflammatory drugs based on ibuprofen and leflunomide molecules.
($1 = 0.8067 euros)
(Reporting by Matthias Blamont and Sudip Kar-Gupta; Editing by Jason Neely and Mark Potter)